U.S. Allows ADHD Drugmaker to Increase Production Limit to Ease Ongoing Shortage

September 4, 2024

a mix of various types of pills

(NBC News) – The Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States.

The raised production limit follows the Food and Drug Administration’s request in July, the DEA said in a notice on Tuesday. (Read More)